Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 8, 2025JCO Oncology Practice

Comparative cardiovascular and hematologic safety of CAR-T cell therapies and bispecific antibodies: A FAERS-based disproportionality analysis (2022–2024).

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAqeeb Ur RehmanWRWania RehmanMSMuhammad Talha Shaukat

Discussion

Loading...

Member takes

Overview

Retrospective pharmacovigilance study finds CAR-T therapies have higher adverse event odds than bispecific antibodies, indicating increased monitoring is essential.

Key Points

  • CAR-T therapies show significantly higher reporting odds of adverse events compared to bispecific antibodies.
  • The analysis included 3,867 adverse event reports, with notable toxicities like myelodysplastic syndrome and cytokine release syndrome.
  • Disproportionality analysis revealed substantial risks linked to CAR-T therapies, emphasizing the need for careful patient monitoring and follow-up.
  • FAERS data highlights the importance of real-world safety signal identification to inform clinical decision-making in immunotherapy.

Cite This Study

Rehman et al. (2025) studied this question.

synapsesocial.com/papers/68e6f342f8145af55aeacca3https://doi.org/10.1200/op.2025.21.10_suppl.444
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative safety profiles of bispecific T-cell engagers and CAR-T therapies: Real-world insights from the FDA adverse event reporting system database2025 · 1 citations
  2. 2Toxicities associated with CAR-T therapy compared with standard treatments in hematologic malignancies: a systematic review and meta-analysis2026
  3. 3Treatment-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia Associated with CAR T-Cell Therapies : A Real-World FAERS Pharmacovigilance Study2026
  4. 4Treatment-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia Associated with CAR T-Cell Therapies: A Real-World FAERS Pharmacovigilance Study2026 · 1 citations
  5. 5Comparative toxicity profile of chimeric antigen receptor T-cell therapy versus bispecific T-cell engagers in multiple myeloma and B-cell lymphomas: A propensity-matched real-world analysis.2026